After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI ...
In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after ...
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning ...
Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.
A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in ...
The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an ...
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A ...
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock ...
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results